UX-DA001
Parkinson's Disease
Phase 1Active, with trials ongoing in China and FDA IND cleared in U.S. (as of April 2025)
Key Facts
Indication
Parkinson's Disease
Phase
Phase 1
Status
Active, with trials ongoing in China and FDA IND cleared in U.S. (as of April 2025)
Company
About UniXell
A Chinese biotech developing autologous iPSC-derived cell therapies for neurodegenerative diseases like Parkinson's.
View full company profileTherapeutic Areas
Other Parkinson's Disease Drugs
| Drug | Company | Phase |
|---|---|---|
| NPT200-11 | Neuropore Therapies | Phase 1 |
| NUZ-001 | Neurizon Therapeutics | Preclinical |
| VXX-301 | Vaxxinity | Preclinical |
| BAN2802 | BioArctic | Phase 1 |
| CNM-Au8 | Clene | Phase 2 |
| hpSC-Derived Neural/Dopaminergic Cells | International Stem Cell | Preclinical/Early Clinical |
| SLS-004 | Seelos Therapeutics | Preclinical |
| SLS-007 | Seelos Therapeutics | Preclinical |
| Parkinson's Disease Portfolio (Platform-derived) | WD Pharmaceutical | Not Disclosed (Likely Preclinical/Early Clinical) |
| Parkinson's Disease Research | ProgenaBiome | Research |
| A9 Dopaminergic Neuron Therapy | Trailhead Biosystems | Pre-clinical |
| golexanolone | Umecrine Cognition | Preclinical |